



AtriCure to Participate at the Canaccord Genuity 39th Annual Growth Conference

July 17, 2019

MASON, Ohio--(BUSINESS WIRE)--Jul. 17, 2019-- [AtriCure, Inc.](#) (Nasdaq: [ATRC](#)), a leading innovator in surgical treatments for atrial fibrillation (Afib) and left atrial appendage management, today announced that the company will be participating in the upcoming Canaccord Genuity 39th Annual Growth Conference in Boston.

AtriCure's management is scheduled to present on Thursday, August 8, 2019, at 11:00 a.m. Eastern Time. Interested parties may access a live audio webcast of the presentation by visiting the "Investors" section of the company's website at <https://ir.atricure.com>.

About AtriCure

AtriCure, Inc. provides innovative technologies for the treatment of Afib and related conditions. Afib affects more than 33 million people worldwide. Electrophysiologists and cardiothoracic surgeons around the globe use AtriCure technologies for the treatment of Afib and reduction of Afib related complications. AtriCure's Isolator[®] Synergy[™] Ablation System is the first and only medical device to receive FDA approval for the treatment of persistent Afib. AtriCure's AtriClip[®] Left Atrial Appendage Exclusion System products are the most widely sold LAA management devices worldwide. For more information, visit AtriCure.com or follow us on Twitter [@AtriCure](#).

View source version on businesswire.com: <https://www.businesswire.com/news/home/20190717005731/en/>

Source: AtriCure, Inc.

Andy Wade
AtriCure, Inc.
Senior Vice President and Chief Financial Officer
(513) 755-4564
awade@atricure.com

Lynn Pieper Lewis
Gilmartin Group
Investor Relations
(415) 937-5402
lynn@gilmartinir.com